The Clinical Significance of Routine Risk Categorization in Metastatic Renal Cell Carcinoma and its Impact on Treatment Decision-Making: A Systematic Review

References

• Bray F , FerlayJ, SoerjomataramI, SiegelRL, TorreLA, JemalA. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin.68(6), 394–424 (2018).
   PubMed Web of Science ®Google Scholar
• Dabestani S , ThorstensonA, LindbladP, HarmenbergU, LjungbergB, LundstamS. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J. Urol.34(8), 1081–1086 (2016).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , PenkovK, HaanenJet al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1103–1115 (2019).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , TannirNM, McDermottDFet al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med.378(14), 1277–1290 (2018).
   PubMed Web of Science ®Google Scholar
• Rini BI , PlimackER, StusVet al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1116–1127 (2019).
   PubMed Web of Science ®Google Scholar
• Escudier B , PortaC, SchmidingerMet al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.30(5), 706–720 (2019).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . Kidney cancer (version 2.2020) (2019). https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf
   Google Scholar
• Gore ME , SzczylikC, PortaCet al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Br. J. Cancer113(1), 12–19 (2015).
   PubMed Web of Science ®Google Scholar
• Noe A , de BruijnRE, BlankC, HorenblasS, HaanenJ, BexA. Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy. World J. Urol.34(8), 1067–1072 (2016).
   PubMed Web of Science ®Google Scholar
• Higgins J , LassersonT, ChandlerJ, ToveyD, ChurchillR. Methodological expectations of cochrane intervention reviews (MECIR) (2016). https://methods.cochrane.org/sites/default/files/public/uploads/Cochrane%20MECIR_Standards%20FINAL%20booklet_web_version.pdf
   Google Scholar
• Liberati A , AltmanDG, TetzlaffJet al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J. Clin. Epidemiol.62(10), e1–e34 (2009).
   PubMed Web of Science ®Google Scholar
• Morrison A , PolisenaJ, HusereauDet al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int. J. Technol. Assess. Health Care28(2), 138–144 (2012).
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network . Search filters: randomised controlled trials (2019). www.sign.ac.uk/search-filters.html
   Google Scholar
• National Institute for Health and Care Excellence . NICE technology appraisal guidance (2018). www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
   Google Scholar
• Wells G , SheaB, O’ConnellD, PetersonJ, WelchV, LososM. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. (2013). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Savard M-F , WellsJC, GrahamJet al. Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group. J. Clin. Oncol.37(Suppl. 7), 610 (2019).
   PubMed Web of Science ®Google Scholar
• Shinohara N , NonomuraK, AbeTet al. A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci.103(9), 1695–1700 (2012).
   PubMed Web of Science ®Google Scholar
• McDermott DF , ChengSC, SignorettiSet al. The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. Clin. Cancer Res.21(3), 561–568 (2015).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , MotzerRJ, CampbellMTet al. Subgroup analysis from JAVELIN Renal 101: outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol.37(Suppl. 7), 544 (2019).
   Web of Science ®Google Scholar
• Kubackova K , MelicharB, BortlicekZet al. Comparison of two prognostic models in patients with metastatic renal cancer treated with sunitinib: a retrospective, registry-based study. Target. Oncol.10(4), 557–563 (2015).
   PubMed Web of Science ®Google Scholar
• Lolli C , BassoU, DerosaLet al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Oncotarget7(34), 54564–54571 (2016).
   PubMedGoogle Scholar
• Rini BI , HutsonTE, FiglinRAet al. Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. Clin. Genitourin. Cancer16(4), 298–304 (2018).
   PubMed Web of Science ®Google Scholar
• Moran M , NickensD, AdcockK, BennettsM, CharnleyN, FifeK. Augmenting the randomized controlled trial with real-world data to aid clinical decision making in metastatic renal cell carcinoma: a systematic review and meta-analysis. Future Oncol.15(34), 3987–4001 (2019).
   PubMed Web of Science ®Google Scholar
• De Giorgi U , RihawiK, AietaMet al. Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. J. Geriatr. Oncol.5(2), 156–163 (2014).
   PubMed Web of Science ®Google Scholar
• Mitchell AP , HarrisonMR, WalkerMS, GeorgeDJ, AbernethyAP, HirschBR. Clinical trial participants with metastatic renal cell carcinoma differ from patients treated in real-world practice. J. Oncol. Pract.11(6), 491–497 (2015).
   PubMed Web of Science ®Google Scholar
• Heng DY , ChoueiriTK, RiniBIet al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann. Oncol.25(1), 149–154 (2014).
   PubMed Web of Science ®Google Scholar
• Marschner N , StaehlerM, MullerLet al. Survival of patients with advanced or metastatic renal cell carcinoma in routine practice differs from that in clinical trials-analyses from the German Clinical RCC Registry. Clin. Genitourin. Cancer15(2), e209–e215 (2017).
   PubMedGoogle Scholar
• Nieder C , SyedMA, DalhaugA, PawinskiA, NorumJ. Eligibility for Phase III clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Med. Oncol.34(9), 149 (2017).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , HesselC, HalabiSet al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur. J. Cancer94, 115–125 (2018).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , HalabiS, SanfordBLet al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN Trial. J. Clin. Oncol.35(6), 591–597 (2017).
   PubMed Web of Science ®Google Scholar
• Kammerer-Jacquet SF , DeleuzeA, SaoutJet al. Targeting the PD-1/PD-L1 pathway in renal cell carcinoma. Int. J. Mol. Sci.20(7), (2019).
   PubMed Web of Science ®Google Scholar
• Lee HJ , ShinDH, LeeYJet al. PD-L1 expression and infiltration by CD4+ and FOXP3+ T cells are increased in Xp11 translocation renal cell carcinoma and indicate poor prognosis. Histopathologydoi:10.1111/his.14047 (2019) ( Epub ahead of print).
   Web of Science ®Google Scholar
• Heng DY , XieW, ReganMMet al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol.14(2), 141–148 (2013).
   PubMed Web of Science ®Google Scholar
• Okita K , HatakeyamaS, TanakaTet al. Impact of disagreement between two risk group models on prognosis in patients with metastatic renal-cell carcinoma. Clin. Genitourin. Cancer17(3), e440–e446 (2019).
   PubMed Web of Science ®Google Scholar
• Sella A , MichaelsonMD, MatczakE, SimantovR, LinX, FiglinRA. Heterogeneity of patients with intermediate-prognosis metastatic renal cell carcinoma treated with sunitinib. Clin. Genitourin. Cancer15(2), 291–299e291 (2017).
   PubMed Web of Science ®Google Scholar
• Fay AP , XieWL, LeeJLet al. Characteristics of long-term and short-term survivors of metastatic renal cell carcinoma treated with targeted therapies: results from the International mRCC Database Consortium. Clin. Genitourin. Cancer13(2), 150–155 (2015).
   PubMed Web of Science ®Google Scholar
• Iacovelli R , DeGiorgi U, GalliLet al. Is It possible to improve prognostic classification in patients affected by metastatic renal cell carcinoma with an intermediate or poor prognosis? Clin. Genitourin. Cancer 16(5), 355–359 (2018).
   PubMed Web of Science ®Google Scholar
• Savard MF , WellsJC, GrahamJet al. Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. Oncologist25(5), 422–430 (2020).
   PubMed Web of Science ®Google Scholar
• Adashek JJ , GenoveseG, TannirNM, MsaouelP. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: a review of the evidence using second-generation p-values. Cancer Treat Res. Commun.23, 100166 (2020).
   PubMedGoogle Scholar
• Sashegyi A , FerryD. On the Interpretation of the Hazard Ratio and Communication of Survival Benefit. Oncologist22(4), 484–486 (2017).
   PubMed Web of Science ®Google Scholar
• Kent DM , SteyerbergE, van KlaverenD. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ363, k4245 (2018).
   PubMedGoogle Scholar
• Heng DY , ChiKN, MurrayNet al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer115(4), 776–783 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , BacikJ, MurphyBA, RussoP, MazumdarM. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol.20(1), 289–296 (2002).
   PubMed Web of Science ®Google Scholar
• Chrom P , StecR, BodnarL, SzczylikC. Incorporating neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in place of neutrophil count and platelet count improves prognostic accuracy of the International Metastatic Renal Cell Carcinoma Database Consortium Model. Cancer Res. Treat.50(1), 103–110 (2018).
   PubMed Web of Science ®Google Scholar
• Tanaka N , MizunoR, YasumizuYet al. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: a proposal of the modified-IMDC risk model. Urol. Oncol.35(2), 39.e19–39.e28 (2017).
   PubMed Web of Science ®Google Scholar
• Schutz FA , XieW, DonskovFet al. The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. Eur. Urol.65(4), 723–730 (2014).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , AlbigesL, HaanenJBAGet al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J. Clin. Oncol.37(Suppl. 15), 101–101 (2019).
   Google Scholar
• McDermott DF , HuseniMA, AtkinsMBet al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med.24(6), 749–757 (2018).
   PubMed Web of Science ®Google Scholar
• Voss MH , ReisingA, ChengYet al. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. Lancet Oncol.19(12), 1688–1698 (2018).
   PubMed Web of Science ®Google Scholar
• de Velasco G , CulhaneAC, FayAPet al. Molecular subtypes improve prognostic value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist22(3), 286–292 (2017).
   PubMed Web of Science ®Google Scholar
• Massari F , NunnoVD, MollicaVet al. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy11(17), 1507–1521 (2019).
   PubMed Web of Science ®Google Scholar
• Mollica V , DiNunno V, GattoLet al. Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor. Cancers (Basel)11(6), (2019).
   Web of Science ®Google Scholar
• Beuselinck B , JobS, BechtEet al. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting. Clin. Cancer Res.21(6), 1329–1339 (2015).
   PubMed Web of Science ®Google Scholar
• Beuselinck B , VerbiestATL, CouchyGet al. Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. Ann. Oncol.29(Suppl. 8), viii303–viii331 (2018).
   Google Scholar
• Cella D , GrunwaldV, EscudierBet al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, Phase III trial. Lancet Oncol.20(2), 297–310 (2019).
   PubMed Web of Science ®Google Scholar
• Donskov F , JensenNV, Smidt-HansenT, BrondumL, GeertsenP. A randomized Phase II trial of interleukin-2 and interferon-alpha plus bevacizumab versus interleukin-2 and interferon-alpha in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. Acta Oncol.57(5), 589–594 (2018).
   PubMed Web of Science ®Google Scholar
• Eichelberg C , VervenneWL, DeSantis Met al. SWITCH: a randomised, sequential, open-label study to evaluate the efficacy and safety of sorafenib-sunitinib versus sunitinib-sorafenib in the treatment of metastatic renal cell cancer. Eur. Urol.68(5), 837–847 (2015).
   PubMed Web of Science ®Google Scholar
• Escudier B , PluzanskaA, KoralewskiPet al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Escudier B , BellmuntJ, NegrierSet al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol.28(13), 2144–2150 (2010).
   PubMed Web of Science ®Google Scholar
• Hudes G , CarducciM, TomczakPet al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Hutson TE , LesovoyV, Al-ShukriSet al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label Phase III trial. Lancet Oncol.14(13), 1287–1294 (2013).
   PubMed Web of Science ®Google Scholar
• Mejean A , RavaudA, ThezenasSet al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med.379(5), 417–427 (2018).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol.27(22), 3584–3590 (2009).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , NosovD, EisenTet al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a Phase III trial. J. Clin. Oncol.31(30), 3791–3799 (2013).
   PubMed Web of Science ®Google Scholar
• Rini BI , HalabiS, RosenbergJEet al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Tannir NM , FronteraOA, HammersHJet al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J. Clin. Oncol.37(Suppl. 7), 547 (2019).
   PubMed Web of Science ®Google Scholar
• Boegemann M , HubbeM, ThomaidouDet al. Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. Anticancer Res.38(11), 6413–6422 (2018).
   PubMed Web of Science ®Google Scholar
• Bozkurt O , HacibekirogluI, KaplanMAet al. Is late recurrence a predictive clinical marker for better sunitinib response in metastatic renal cell carcinoma patients? Clin. Genitourin. Cancer 13(6), 548–554 (2015).
   PubMed Web of Science ®Google Scholar
• Coelho RC , ReinertT, CamposFet al. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience. Int. Braz J. Urol.42(4), 694–703 (2016).
   PubMed Web of Science ®Google Scholar
• De Giorgi U , ScarpiE, SaccoCet al. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. Clin. Genitourin. Cancer12(3), 182–189 (2014).
   PubMed Web of Science ®Google Scholar
• Harshman LC , KroegerN, RhaSYet al. First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin. Genitourin. Cancer12(5), 335–340 (2014).
   PubMed Web of Science ®Google Scholar
• Joshi A , RamaswamyA, NoronhaVet al. Efficacy and safety of sorafenib in advanced renal cell cancer and validation of Heng criteria. Indian J. Cancer53(3), 423–428 (2016).
   PubMed Web of Science ®Google Scholar
• Lalani AA , LiH, HengDYCet al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience. Can. Urol. Assoc. J.11(3–4), 112–117 (2017).
   PubMed Web of Science ®Google Scholar
• Omae K , KondoT, KennokiTet al. Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis. Int. J. Clin. Oncol.21(1), 126–132 (2016).
   PubMed Web of Science ®Google Scholar
• Perez-Valderrama B , ArranzArija JA, RodriguezSanchez Aet al. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study. Ann. Oncol.27(4), 706–711 (2016).
   PubMed Web of Science ®Google Scholar
• Santoni M , ContiA, PortaCet al. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma. J. Urol.193(1), 41–47 (2015).
   PubMed Web of Science ®Google Scholar
• Sastre-Heres AJ , CaleroMA, Ruiz-SanchezDet al. Study of the effectiveness of first-line treatment in renal cell carcinoma. Mol. Clin. Oncol.2(6), 1167–1171 (2014).
   PubMedGoogle Scholar
• Schmidinger M , PortaC, OudardSet al. Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: clinical outcome according to risk score. J. Clin. Oncol.37(Suppl. 7), 606 (2019).
   Web of Science ®Google Scholar
• Stenehjem DD , TooleM, MerrimanJet al. Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. Cancer Immunol. Immunother.65(8), 941–949 (2016).
   PubMed Web of Science ®Google Scholar
• Warren M , VennerPM, NorthSet al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can. Urol. Assoc. J.3(4), 281–289 (2009).
   PubMed Web of Science ®Google Scholar
• Yildiz I , SenF, KilicLet al. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma. Curr. Oncol.20(6), e546–e553 (2013).
   PubMed Web of Science ®Google Scholar
• Zhang X , SunG, ZhaoJet al. Improved long-term clinical outcomes and safety profile of sunitinib dosing schedule with 4/2 switched to 2/1 in patients with metastatic renal cell carcinoma. J. Cancer9(18), 3303–3310 (2018).
   PubMed Web of Science ®Google Scholar
• McDermott DF , LeeJL, SzczylikCet al. Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427. J. Clin. Oncol.36(Suppl. 15), 4500 (2018).
   Google Scholar
• Melichar B , BracardaS, MatveevVet al. A multinational Phase II trial of bevacizumab with low-dose interferon-alpha2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann. Oncol.24(9), 2396–2402 (2013).
   PubMed Web of Science ®Google Scholar
• Zurita AJ , RossJA, DevineCEet al. A randomized Phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial). J. Clin. Oncol.36(Suppl. 15), 4563 (2018).
   Web of Science ®Google Scholar